Showing Results for
- Academic Journals (23)
Search Results
- 23
Academic Journals
- 23
- Search Terms:ISSN: 14655411AndISSN: 1465542XAndVolume Number: 13AndIssue Number: 6AndStart Page: R129AndDate: 2011 Revise Search
- 1From: Breast Cancer Research. (Vol. 13, Issue 6) Peer-ReviewedThe epithelial-to-mesenchymal transition (EMT) is a critical developmental process that has recently come to the forefront of cancer biology. In breast carcinomas, acquisition of a mesenchymal-like phenotype that is...
- 2From: Breast Cancer Research. (Vol. 13, Issue 6) Peer-ReviewedIntroduction Triple-negative breast cancers (TNBCs) are characterised by lack of expression of hormone receptors and epidermal growth factor receptor 2 (HER-2). As they frequently express epidermal growth factor...
- 3From: Breast Cancer Research. (Vol. 13, Issue 6) Peer-ReviewedEarly detection of metastasis-prone breast cancers and characterization of residual metastatic cancers are important in efforts to improve management of breast cancer. Applications of genome-scale molecular analysis...
- 4From: Breast Cancer Research. (Vol. 13, Issue 6) Peer-ReviewedVariations in percent mammographic density (PMD) reflect variations in the amounts of collagen and number of epithelial and non-epithelial cells in the breast. Extensive PMD is associated with a markedly increased risk...
- 5From: Breast Cancer Research. (Vol. 13, Issue 6) Peer-ReviewedGene expression profiling has led to a new molecular classification of breast cancer characterized by four intrinsic subtypes: basal-like, HER2-positive, luminal A, and luminal B. Despite expressing estrogen receptor,...
- 6From: Breast Cancer Research. (Vol. 13, Issue 6) Peer-ReviewedMost breast cancer patients die due to metastases, and the early onset of this multistep process is usually missed by current tumor staging modalities. Therefore, ultrasensitive techniques have been developed to enable...
- 7From: Breast Cancer Research. (Vol. 13, Issue 6) Peer-ReviewedIntroduction Previous studies have demonstrated that common breast cancer susceptibility alleles are differentially associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. It is currently unknown...
- 8From: Breast Cancer Research. (Vol. 13, Issue 6) Peer-ReviewedIntroduction The human epidermal growth factor receptor 2 (HER2)-targeted therapies trastuzumab (T) and lapatinib (L) show high efficacy in patients with HER2-positive breast cancer, but resistance is prevalent. Here...
- 9From: Breast Cancer Research. (Vol. 13, Issue 6) Peer-ReviewedEpigenetic changes are critical for development and progression of cancers, including breast cancer. Significant progress has been made in the basic understanding of how various epigenetic changes such as DNA...
- 10From: Breast Cancer Research. (Vol. 13, Issue 6) Peer-ReviewedConsistent with their essential role in cell adhesion to the extracellular matrix, integrins and their associated signaling pathways have been shown to be involved in cell proliferation, migration, invasion and...
- 11From: Breast Cancer Research. (Vol. 13, Issue 6) Peer-ReviewedBackground Mutations in the BRCA1 and BRCA2 genes are responsible for only a part of hereditary breast cancer (HBC). The origins of "non-BRCA" HBC in families may be attributed in part to rare mutations in genes...
- 12From: Breast Cancer Research. (Vol. 13, Issue 6) Peer-ReviewedMutations in genes that constitute the phosphatidylinositol 3-kinase (PI3K) pathway occur in >70% of breast cancers. Clinical and experimental evidence suggest that PI3K pathway activation promotes resistance to some of...
- 13From: Breast Cancer Research. (Vol. 13, Issue 6) Peer-ReviewedIntroduction Inhibiting the enzyme Fatty Acid Synthase (FASN) leads to apoptosis of breast carcinoma cells, and this is linked to human epidermal growth factor receptor 2 (HER2) signaling pathways in models of...
- 14From: Breast Cancer Research. (Vol. 13, Issue 6) Peer-ReviewedAuthor(s): Lewis A Chodosh1 Over the past 50 years, deaths from cardiovascular disease, stroke and pneumonia have plummeted as a result of new therapies and preventive strategies based upon a detailed understanding...
- 15From: Breast Cancer Research. (Vol. 13, Issue 6) Peer-ReviewedIntroduction The PACS01 trial has demonstrated that a docetaxel addition to adjuvant anthracycline-based chemotherapy improves disease-free survival (DFS) and overall survival of node-positive early breast cancer...
- 16From: Breast Cancer Research. (Vol. 13, Issue 6) Peer-ReviewedTwo recent studies on a rare androgen-dependent form of breast cancer have shed light on the biology of luminal tumours and reinforced the view that interfering with androgen signalling may have a place in the therapy...
- 17From: Breast Cancer Research. (Vol. 13, Issue 6) Peer-ReviewedIntroduction Response to trastuzumab in metastatic breast cancer correlates with expression of the high binding variant (158V) of the activating Fc[gamma] receptor IIIA (CD16A). We engineered MGAH22, a chimeric...
- 18From: Breast Cancer Research. (Vol. 13, Issue 6) Peer-ReviewedBreast cancer comprises a heterogeneous group of malignancies derived from the ductal epithelium. The microenvironment of these cancers is now recognized as a critical participant in tumor progression and therapeutic...
- 19From: Breast Cancer Research. (Vol. 13, Issue 6) Peer-ReviewedIntroduction In contrast to its role in breast cancer (BCa) initiation, estrogen signaling has a protective effect in later stages, where estrogen receptor (ER)[alpha] loss associates with aggressive metastatic...
- 20From: Breast Cancer Research. (Vol. 13, Issue 6) Peer-ReviewedIntroduction Estrogen is involved in several physiological and pathological processes through estrogen receptor (ER)-mediated transcriptional gene regulation. miRNAs (miRs), which are noncoding RNA genes, may respond...